Infergen (interferon alfacon-1)
- Region
- 🇪🇺 EU
- Active substance
- interferon alfacon-1
- Company
- Astellas Pharma Europe B.V.
- Status
- Withdrawn
- Therapeutic area
- Hepatitis C, Chronic
- EU approval
- Mon 01 Feb 1999
- Application
- EMEA/H/C/000186
- ATC
- L03AB09
- Official record
- www.ema.europa.eu
Indication
Treatment of patients of 18 years and older with chronic hepatitis and serum markers for hepatitis C virus (HCV) infection e.g. those who have elevated serum transaminase levels without decompensated liver disease and who are positive for serum HCV-RNA (see section 4.4). Consideration should be given to current official guidance on the appropriate use of interferons for the treatment of patients with chronic hepatitis C.Interferon alfacon-1 should be given alone mainly in case of intolerance or contraindication to ribavirin.
Regulatory milestones
No milestones recorded in the last year.
Follow Infergen
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.